Skip to content

Author

D. Tougeron

We have 4 of 40 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

First-line fluoropyrimidine- versus gemcitabine-based chemotherapy for metastatic recurrence after resection of ampullary adenocarcinoma: A real-world analysis of the FFCD-AC cohort.

INTRODUCTION Ampullary adenocarcinoma (AC) is a rare malignancy with limited evidence to guide systemic treatment in the metastatic setting. METHODS This post hoc analysis was conducted within the French national prospective FFCD-AC cohort, which enrolled patients undergoing curative-intent resection for localized AC...

E. Vo-Quang, V. Hautefeuille, O. Bouché et al. · 0 citations
Clinical trial Open access Sep 2026

First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306)

RATIONALE-306 previously demonstrated improved overall survival (OS) in participants treated with tislelizumab plus chemotherapy versus those receiving placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma, with a minimum follow-up of approximately 15 months. Explo...

H. Yoon, Ken Kato, E. Raymond et al. · 0 citations
Open access Aug 2026

Tislelizumab plus chemotherapy for advanced or metastatic esophageal squamous-cell carcinoma in patients with PD-L1 Tumor Area Positivity score ≥5%: a post hoc, exploratory, long-term follow-up of RATIONALE-306☆

First-line tislelizumab plus chemotherapy provided sustained and clinically meaningful efficacy benefits over placebo plus chemotherapy and was tolerable, with no new safety signals for patients with unresectable, locally advanced, or metastatic ESCC and PD-L1 TAP score ≥5%.

D. Tougeron, J. Xu, E. Raymond et al. · 0 citations
Aug 2026

Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC.

High baseline circulating and tumor γδ T cells and early circulating CD8⁺PD-1⁺ T Cell expansion were associated with better outcome under AtezoBev, and an early induction of T cell-associated interferon-γ signaling at 3 weeks after the first injection of AtezoBev in patients that experienced response.

I. Galy-Fauroux, A. Asif-Laidin, M. Evain et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.